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Background: The PALB2 c.2323C>T [p.Q775X] mutation has been reported in at least three breast cancer families
and breast cancer cases of French Canadian descent and this has been attributed to common ancestors. The
number of mutation-positive cases reported varied based on criteria of ascertainment of index cases tested.
Although inherited PALB2 mutations are associated with increased risks of developing breast cancer, risk to ovarian
cancer has not been fully explored in this demographically unique population.
Methods: We screened the PALB2 p.Q775X variant in 71 families with at least three cases of breast cancer (n=48) or
breast and ovarian cancers (n=23) that have previously been found negative for at least the most common BRCA1
and BRCA2 mutations reported in the French Canadian population and in 491 women of French Canadian descent
who had invasive ovarian cancer and/or low malignant potential tumors of the major histopathological subtypes.
Results: We identified a PALB2 p.Q775X carrier in a breast cancer family, who had invasive ductal breast carcinomas
at 39 and 42 years of age. We also identified a PALB2 p.Q775X carrier who had papillary serous ovarian
cystadenocarcinoma at age 58 among the 238 serous subtype ovarian cancer cases investigated, who also had
breast cancer at age 52.
Conclusion: Our findings, taken together with previous reports, support adding PALB2 c.2323C>T p.Q775X to the
list of cancer susceptibility genes for which founder mutations have been identified in the French Canadian
population.
Keywords: PALB2, p.Q775X, p.Q775*, Hereditary breast cancer, Breast cancer risk, Ovarian cancer, Founder mutations,
French CanadiansBackground
Carriers of PALB2 mutations in a heterozygous state
have been associated with increasing the risk of devel-
oping breast cancer [1-10]. PALB2 is a partner and loca-
lizer of the BRCA2 breast-ovarian cancer susceptibility
protein to DNA damage sites [9,11]. Penetrance estima-
tion for conferring breast cancer risk has been hampered* Correspondence: mdt33@cam.ac.uk
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distribution, and reproduction in any mediumby the paucity of cases, although estimates of 2- to 6-fold
increased risk to breast cancer have been suggested
[12,13], thus classifying PALB2 as a moderate breast can-
cer risk allele [9,12-14]. Germline mutations in PALB2
have also been identified in familial pancreatic cancer
[15,16]. PALB2 is comprised of 13 exons spanning a 38 kb
region on chromosome 16p12.1 and mutation screening is
complicated by the diversity of variants (including mis-
sense mutations) identified in cancer cases. The PALB2
c.2323C>T mutation, which results in the introduction of
a stop codon at amino acid position 775 (p.Q775X), has
been reported in at least three French Canadian breastntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ing PALB2 mutations found in breast cancer cases, is
strongly suspected to be deleterious [17]. The French
Canadian population of Quebec exhibits an unique gen-
etic demography [18-20]. About 40% of French Canadian
cancer families with at least three cases of breast and/
ovarian cancer carry a pathogenic BRCA1 or BRCA2 mu-
tation [20-25]. Although 15 different mutations in these
genes have been reported in French Canadian cancer fam-
ilies, six specific mutations in BRCA1 and BRCA2 have
been shown to account for a significant majority of
mutation-positive families [20-26]. This has been attribu-
ted to a shared ancestry of mutation carriers due to com-
mon founders of the French Canadian population of
Quebec [25-28].
The number of PALB2 p.Q775X mutation-positive cases
that have been reported thus far in studies involving the
French Canadian population vary according to criteria
and catchment area of ascertainment of index breast cases
tested [5,29]. To further assess the contribution of PALB2
p.Q775X mutation in the French Canadian population, we
report the results of screening this variant in 71 well
defined cancer families with at least three confirmed cases
of breast and/ovarian cancer found negative for the most
common BRCA1 and BRCA2 mutation reported in this
population. We report the cancer phenotype of a new p.
Q775X mutation-positive family. We also report the
screening 385 invasive ovarian cancer cases and 106 low
malignancy potential ovarian tumors not selected for fam-
ily history of cancer that were ascertained from the French
Canadian population, and describe the cancer history of
the p.Q775X cases identified in this screen. We describe
our findings in the context of previous studies describing
mutation screens of PALB2 in individuals of French
Canadian descent.
Methods
Subjects and cancer families
The study subjects fall within two defined groups. The
first group contains index cases from 71 independently
ascertained families (Table 1). The index cases tested for
mutations were recruited to the study through the her-
editary cancer clinics in Montreal as part of research
studies assessing the contribution of BRCA1 and
BRCA2 in breast and/or ovarian cancer families asTable 1 Families and features of index cases screened for PAL
Syndrome Number of
families1
Unilateral
BC
Bilateral
BC
BC an
OC
HBC 48 [10] 45 3 0
HBOC 23 [4] 14 2 1
Total 71 [14] 59 5 1
1The numbers in the brackets refer to number of index cases where the complete c
(BC), hereditary breast cancer (HBC) hereditary breast and ovarian cancer (HBOC), andescribed previously [21,25]. They have a family history
of breast cancer (n= 48) or breast and ovarian cancer
(n=23) according to the following criteria: in addition to
the index case affected with breast cancer at less than
66 years of age, the families contained at least two other
confirmed cases of invasive breast and/or epithelial ovar-
ian cancer in the same familial branch. The affected index
cases from 26 breast cancer families (HBC) and 14 breast-
ovarian cancer (HBOC) families were previously screened
and found negative for BRCA1 and BRCA2 sequence var-
iants by commercial DNA sequencing (Myriad Genetics,
Myriad Genetics Laboratories, Salt Lake City, UT, USA).
The index affected cases from the remaining 22 HBC and 9
HBOC families were found negative for 20 BRCA1 and
BRCA2 mutations reported in French Canadian cancer
families of Quebec which include the following most
common BRCA1 (c.4327C>T (R1443X), c.2834_2836delG-
TAinsC) and BRCA2 (c.8537_8538delAG, c.5857G>T
(E1953X), c.3167_3171delAAAAG) mutations reported in
this population, as described previously [22,23,25]. All
index cases in this study self-reported grandparental
French Canadian ancestry. The second group contained
385 females with epithelial ovarian carcinomas and 106
low malignant potential tumors (Table 2), who were
recruited to Banque de tissus et de données of the RRCan-
cer of the Fonds recherché Québec-santé tumor bank
between April 1991 and October 2007. At least 88% of all
women with malignant serous, endometrioid or undiffer-
entiated malignant ovarian cancer cases from RRCancer
Tumor self reported French Canadian ancestry (unpub-
lished data). All women with serous LMP (Low Malignant
Potential) tumors self-reported FC ancestry [30]. None of
these subjects were selected for family history of cancer.
Histopathology according to criteria established by the
International Federation of Gynecology and Obstetrics
(FIGO), age at diagnosis and personal history of cancer
were provided for each case. Written consent to participate
was obtained and the study protocols approved by the
ethics review boards of the University of Montreal Hospital
Center, McGill University Health Centre and Jewish
General Hospital.
PALB2 mutation analysis
Mutation analysis was performed on DNA extracted from
peripheral blood leukocytes or from fresh frozen tumorB2 c.2323C>T [p.Q775X] variant
d OC Mean age in years of
BC (age range)
Mean age in years of
OC (age range)
0 46 (30–65) n/a
6 44 (25–55) 51 (31–74)
6 46 (25–65) 51 (31–74)
oding region of PALB2 genes was sequenced. Abbreviations: breast cancer
d ovarian cancer (OC).
Table 2 Features of ovarian tumors examined for PALB2
c.2323C>T [p.Q775X] mutation
Malignancy Histology type Number of
cases
Prior history
of BC
Malignant serous 238 10
Malignant endometrioid 49 2
Malignant mucinous 24 2
Malignant clear cell 31 2
Malignant undifferentiated 43 1
Low malignant potential serous 56 4
Low malignant potential endometrioid 2 0
Low malignant potential mucinous 48 0
Total 491 21
Abbreviation: breast cancer (BC).
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PALB2 for the index cases of 14 families was performed as
described previously [5,10,17] (Table 1). The targeted ana-
lysis for PALB2 c.2323C>T (p.Q775X) variant was per-
formed using an allelic specific assay as described [5]. The
variant-positive cases were confirmed by DNA sequencing
using 3730XL DNA analyzer system platform from Ap-
plied Biosystems (Carlbad, CA, USA) at the McGill Univer-
sity and Genome Quebec Innovation Centre (Montreal,
PQ, CDN). Sequences were compared with PALB2 NCBI
Reference Sequence NM_024675 as described in GenBank
(www.ncbi.nlm.nih.gov). For the Loss of heterozygosity
(LOH) analysis, fresh frozen ovarian tumor tissue from the
PALB2 p.Q775X mutation-positive case was macrodis-
sected and DNA was extracted from the collected cells
using the QIAamp DNA Mini Kit (Qiagen). The PCR was
carried out in a volume of 50 μL, as previously described
[5,10]. Sequence data were analyzed using the Lasergene
SeqMan Pro sequence analysis software by DNASTAR,
Inc. (Madison, WI, USA) and Chromas 2.31 from Techne-
lysium Pty Ltd. (Helensvale, Australia) and compared to
the sequences from lymphocyte DNA from PALB2 p.
Q775X mutation-positive and mutation-negative cases.
The PALB2 p.Q775X variant is also annotated as p.
Q775* according to a recently proposed nomenclature
alteration for nonsense changes by the Human Genome
Variation Society (www.hgvs.org). However for histor-
ical purposes the p.Q775X designation is maintained in
this report.
Results
PALB2 c.2323C>T [p.Q775X] carriers in breast and/or
ovarian cancer families
One PALB2 p.Q775X positive case was identified among
the cancer families not previously investigated for PALB2
mutations. The index carrier case was identified among
the total of 48 (2.1%) HBC families or 71 (1.4%) HBC and
HBOC families that share a phenotype defined by at leastthree or more confirmed cases of breast and/or ovarian
cancer in the same familial branch (Table 1). These
families were previously found negative for BRCA1 and
BRCA2 mutations or the most common pathogenic
mutations in these genes found in the French Canadian
population.
The PALB2 carrier had bilateral invasive ductal carcin-
omas of the breast at ages 39 and 42 and is part of the
breast cancer family F1469 (Figure 1). Although breast
cancer was reported in both paternal and maternal
branches of her family (Figure 1), only the aunt and cousin
from the paternal branch of the family were confirmed to
have had breast cancer. Her paternal aunt also had bilat-
eral invasive ductal carcinoma at ages 41 and 42, as well
as atypical stomach carcinoma that was identified at age
42 but not further explored due to death soon thereafter.
The carrier’s paternal cousin had an invasive breast cancer
of mixed ductal and lobular histopathology at 52 and was
still living at the time of pedigree analysis. Notable in this
pedigree is that lack of ovarian cancer cases typified by
BRCA1 or BRCA2 mutation carrier families. Her father
had esophageal cancer and cancers of other sites reported
(some confirmed) for both branches of her family. To our
knowledge no other cases are available for genetic testing
and thus transmission of the mutation is uncertain in this
family. The family structure and associated phenotypes
does not appear to overlap previously described PALB2 p.
Q775X positive families [5].
PALB2 c.2323C>T [p.Q775X] carriers in ovarian cancer
cases
One PALB2 p.Q775X positive case was identified among
the 491 women with ovarian cancer or low malignant
potential tumors. The carrier was diagnosed with a pap-
illary serous cystadenocarcinoma at age 58. The carrier
was identified among the 385 (0.3%) invasive ovarian
carcinomas of all histopathological subtypes and among
238 (0.4%) invasive serous ovarian carcinomas (Table 2).
There were 21 cases that also had a prior personal
history of breast cancer and the PALB2 p.Q775X carrier
was in the group of 10 invasive serous ovarian carcin-
oma cases with this history (Table 2). The carrier had a
breast cancer at age 52 years of undisclosed histological
type. Genetic analysis of genomic DNA from ovarian
cancer specimens did not indicate LOH of the PALB2
locus (Figure 2) or identify a second mutation in the
other coding exons of PALB2.
Discussion
Our results are consistent with previously established
frequency of PALB2 c.2323C>T [p.Q775X] carriers in
breast cancer families of French Canadian descent
(Table 3). Initial reports of comprehensive screening of
all of the protein encoding exons of PALB2, identified
22 3 3 2 3 2
4
67
Mel 45
87
Br 82
46
Bi Br 39-42
44 48-50
d. 66
Eso 66
74d. 43
Bi Br 41-42
St 42
63
d. 51
59
Br 52
d. 70 d. 73
Lu 73
d. 67
Lu 63
d. 40
CH
85
Br 77
d. 77
Ut 77
d. 68
Lu 68
67
Mel 45
d. 77
d. 77 d. 78d.75 d. 59
F1469
Figure 1 Pedigree of PALB2 c.2323C>T [p.Q775X] mutation carrier family F1469. An arrow indicates the proband and only known mutation
carrier in family F1469. Abbreviations: bilateral breast cancer (Bi Br), cerebral hemorrhage (CH) esophageal cancer (Eso), lung cancer (Lu),
melanoma (Mel), stomach cancer (Sto), and uterine cancer (Ut). Age at ascertainment and/or death (d.) are indicated if known along with ages at
diagnosis of cancer.
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ilies had a prior probability of greater than 10% of har-
boring a BRCA1 or BRCA2 mutation [10]. The same
group reported one of 50 (2%) breast cancer families, and
two of 356 (0.6%) cases of early age (< 50 years) breast can-
cer with this mutation [5]. Pedigree analysis of the index
PALB2 p.Q775X positive cases from these three families
indicated that they are not immediately related to each
other and haplotype analysis was consistent with this being
a founder mutation [5]. Four PALB2 p.Q775X positiveA
B
C
Figure 2 Mutation analysis of PALB2 c.2323C>T [p.Q775X]
containing region. DNA sequencing chromatogram showing the
region containing the c.2323C sequence of normal reference sample
(Panel A) and corresponding interval from lymphocyte DNA of
c.2323 T mutation carrier (Panel B) and ovarian cancer specimen
DNA from the same patient (Panel C). The arrow indicates the
position of the mutation in the sequence chromatogram.cases were also identified in a subsequent study involving
564 (0.7%) breast cancer cases not selected for family his-
tory of cancer, which also showed that 6% of cases har-
bored common BRCA1, BRCA2 or CHEK2 mutations [29].
This latter study also included the 356 early age breast can-
cer cases reported in a previous study, and one of these
cases was found related to a member of previously
reported mutation-positive family (P28031) and two other
cases were the same carriers identified in a same previous
study (P31030 and P26007) [5] (Table 3). In an independ-
ent study involving the investigation of a new BRCA2 vari-
ant, c.9004 G>A (E3002K), a family (F1573) harboring
both a BRCA2 variant and the PALB2 p.Q775X mutation
was reported [22]. However, pedigree inspection revealed
that family F1573 was related to one of three PALB2 p.
Q775X (P28031) families described in the initial report of
this variant in the French Canadian breast cancer families
[5]. The family history of PALB2 p.Q775X carrier P36470
also identified in a screen of 564 breast cancer cases not
selected for family history [29] appears not to be related to
the PALB2 p.Q775X carrier families described based on
pedigree inspection, including family F1469 reported in
this study. In summary, six PALB2 p.Q775X breast cancer
carriers which include five occurring in apparently unre-
lated cancer families have thus far been identified in
screening breast cancer cases or breast cancer families.
In contrast, no PALB2 variants were reported in two
other independent studies involving 99 [31] and 21 [2] in-
dependently ascertained breast cancer families of French
Canadian descent. Genealogy and genetic studies have
reported variability of founder effects in various regions of
Quebec [32], suggesting that demography may also be a
factor in the paucity of PALB2 p.Q775X carriers in some
studies of French Canadian cancer families. The majority
of our cases were ascertained in Montreal [20], whereas
independent groups have ascertained their families from
the Quebec City region [31]. This possibility could also
account for the lack of PALB2 p.Q775X carriers found in
a screen of 6,440 newborns of French Canadian descent as
Table 3 Summary of PALB2 c. 2323C>T [p.Q775X] carriers identified in studies of French Canadian cancer families or
cases
p.Q775X
positive cases
Features of p.Q775X
positive case
[Family number]
Number of index
cases screened
Context and feature of cases
or families tested
BRCA1 and BRCA2
status
Reference
0 22 HBC and HBOC families; BRCAPRO
scores > 0.10
Mutation-negative
families
[10]
0 16 HBC and HBOC families; BRCAPRO
scores < 0.10
Mutation-negative
families
[10]
1 BC 54 [P280311 and
(F15732)]
50 BC < 50 years of age, or BC between
50–65 yrs of age with at least one
other BC or OC in first or second
degree relative
Mutation-negative
families
[5] ([22])
2 BC 36 [P260071] BC 49
[P310301]
3562 BC <50 years Common French
Canadian mutation
negative
[5]
4 BC 36 [P260071] BC 46
[P280311] BC 49
[P310301] BC 49
[P36470]
5642 BC <50 years Common French
Canadian mutation
negative
[29]
0 99 High risk BC families Mutation negative [31]
0 21 HBC and HBOC families with at least
2 first/second degree relatives with
BC
Mutation negative [2]
1 BiBC 39–42 [F1469] 48 HBC families (see Table 1) Mutation-negative or
common French
Canadian mutation
negative
This study
0 23 HBOC families (see Table 1) Mutation-negative or
common French
Canadian mutation
negative
This study
1 BC52;OC58 491 OC (see Table 2) Not known This study
1 Indicates cases identified in the pedigrees identified in independent studies involving 356 BC cases investigated in Foulkes et al. [5] overlap with series of 564
BC cases examined in a subsequent study reported by Ghadirian et al. [29]. 2Pedigrees P28031 and F1573 have related family members and were reported in
independent studies [5,22]. Pedigree P28031 had two mutation-positives cancer cases, one as part of HBC family (BC 54) and the other recruited through BC<50
(BC 46) series. Abbreviations: breast cancer (BC), bilateral breast cancer (BiBC) ovarian cancer (OC) hereditary breast cancer (HBC), hereditary breast and ovarian
cancer (HBOC).
Tischkowitz et al. BMC Medical Genetics 2013, 14:5 Page 5 of 7
http://www.biomedcentral.com/1471-2350/14/5the majority of these newborns were from the Quebec
City region [5].
The young ages of breast cancer diagnoses and num-
ber of breast cancer cases per family in PALB2 p.Q775X
carrier families suggest that carriers of this mutation are
at high risk for breast cancer (Table 3), as has been pos-
ited with some PALB2 mutation carrier families [5,10,17].
Our findings here support this notion, as the PALB2 p.
Q775X carrier identified had a bilateral case of breast
cancer diagnosed before age 45 years and a strong family
history of breast cancer (Figure 1).
It is interesting that the PALB2 p.Q775X carrier found
among the ovarian cancer cases examined in this study
had a prior history of breast cancer (Table 3). Notable is
that her personal history of cancer does not match any of
the cases that appear in the pedigrees of PALB2 p.Q775X
positive French Canadian cancer families described thus
far (including the new carrier family identified in this
study). The role of PALB2 in ovarian cancer is uncertain,as there have been few documented ovarian carcinoma
cases harboring germline mutations in this gene. Two
PALB2 mutation carriers were identified in a study of 339
unrelated ovarian cancer cases of Polish descent [3]. The
carriers had high grade carcinomas of different histo-
pathological types: serous (case diagnosed at 61 years) and
endometrioid (case diagnosed at 54 years) subtypes, where
the latter carrier also harbored a BRCA2 mutation [3].
Two (0.6%) PALB2 mutation carriers were reported in a
study of 360 ovarian cancer cases that were also screened
for BRCA1, BRCA2 and other recently described cancer
susceptibility genes [33]. Neither of these two high-grade
serous carcinoma PALB2 mutation-carriers (diagnosed at
ages 51 and 58) had a personal history of breast cancer, al-
though the ovarian cancer case diagnosed at age 58 years
had a family history of breast and/or ovarian cancer [33].
A low frequency of PALB2 carriers (0.4%) was also re-
cently reported in an investigation of 253 ovarian cancer
cases from the Volga-Ural region of Russia [34], with the
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(moderate grade) serous ovarian carcinoma at age 46 and
a prior history of melanoma. The low frequency of PALB2
mutation carriers identified thus far may argue a minor
role for this gene in conferring ovarian cancer risk com-
pared with higher frequency of mutation carriers observed
in breast cancer cases and breast cancer families. This is
consistent with recent findings estimating that PALB2 het-
erozygotes were 1.3-fold more likely to have a relative with
ovarian cancer in the context of HBOC family history [2].
Our genetic analyses of the carrier ovarian cancer speci-
men harboring the PALB2 p.Q775X mutation did not
exhibit evidence of LOH of the PALB2 locus. This could
also be consistent with sufficient contamination of normal
stromal DNA such that it would obscure an imbalance of
alleles. It has been suggested that PALB2 contributes to
carcinogenesis through haploinsufficiency and/or a dom-
inant negative effect given the paucity of LOH observed in
the majority of breast cancer cases from PALB2 carriers
[3,4,6,10], with the exception of one study where a high
frequency of LOH was seen [2]. LOH was observed for
both ovarian cancer cases identified in one study [33].
Promoter methylation silencing has also been reported in
four of 53 sporadic ovarian cancer cases [35]. The signifi-
cance of these findings is unknown and warrants further
investigation to elucidate the role of PALB2 in both breast
and ovarian carcinogenesis.
Conclusion
The PALB2 c.2323C>T [p. Q775X] mutation confers
increased risk for breast cancer in the French Canadian
population of Quebec. The contribution of PALB2
c.2323C>T [p. Q775X] to the causation of breast cancer
in French-Canadians appears to be lesser than that
attributable to the most common founder alleles in
BRCA1 and BRCA2, but the young age at diagnoses and
associated familial history of breast cancer suggest that
this variant should be added to the panel of deleterious
mutations screened for assessing breast cancer risk in
this unique population. Indeed during the preparation of
this manuscript another PALB2 carrier harboring the p.
Q775X variant was identified in the Hereditary Cancer
Clinics affiliated with McGill University Health Centre.
The carrier had bilateral breast cancer at ages 34 and
42 years and a strong family history of breast cancer
further supporting the notion that PALB2 p.Q775X
carriers are at increased risk for breast cancer.
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